Molecular imaging predicts lack of T-DM1 response in advanced HER2-positive breast cancer (final results of ZEPHIR trial).

Journal

NPJ breast cancer
ISSN: 2374-4677
Titre abrégé: NPJ Breast Cancer
Pays: United States
ID NLM: 101674891

Informations de publication

Date de publication:
06 Jan 2024
Historique:
received: 12 05 2023
accepted: 04 12 2023
medline: 7 1 2024
pubmed: 7 1 2024
entrez: 6 1 2024
Statut: epublish

Résumé

Efficacy of the human epidermal growth factor receptor (HER)2-targeting trastuzumab emtansine (T-DM1) in breast cancer (BC) relies on HER2 status determined by immunohistochemistry or fluorescence in-situ hybridization. Heterogeneity in HER2 expression, however, generates interest in "whole-body" assessment of HER2 status using molecular imaging. We evaluated the role of HER2-targeted molecular imaging in detecting HER2-positive BC lesions and patients unlikely to respond to T-DM1. Patients underwent zirconium-89 (

Identifiants

DOI: 10.1038/s41523-023-00610-6 PMID: 38184611
pubmed: 38184611
doi: 10.1038/s41523-023-00610-6
pii: 10.1038/s41523-023-00610-6
doi:

Types de publication

Journal Article

Langues

eng

Pagination

4

Informations de copyright

© 2024. The Author(s).

Références

Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424 (2018).
doi: 10.3322/caac.21492 pubmed: 30207593
Loibl, S. & Gianni, L. HER2-positive breast cancer. Lancet 389, 2415–2429 (2017).
doi: 10.1016/S0140-6736(16)32417-5 pubmed: 27939064
Junttila, T. T., Li, G., Parsons, K., Phillips, G. L. & Sliwkowski, M. X. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res. Treat. 128, 347–356 (2011).
doi: 10.1007/s10549-010-1090-x pubmed: 20730488
Verma, S. et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med. 367, 1783–1791 (2012).
doi: 10.1056/NEJMoa1209124 pubmed: 23020162 pmcid: 5125250
von Minckwitz, G. et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N. Engl. J. Med. 380, 617–628 (2019).
doi: 10.1056/NEJMoa1814017
Wolff, A. C. et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline focused update. Arch. Pathol. Lab. Med. 142, 1364–1382 (2018).
doi: 10.5858/arpa.2018-0902-SA pubmed: 29846104
Seol, H. et al. Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance. Mod. Pathol. 25, 938–948 (2012).
doi: 10.1038/modpathol.2012.36 pubmed: 22388760
Miglietta, F. et al. Evolution of HER2-low expression from primary to recurrent breast cancer. NPJ Breast Cancer 7, 137 (2021).
doi: 10.1038/s41523-021-00343-4 pubmed: 34642348 pmcid: 8511010
Gennari, A. et al. ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann. Oncol. 32, 1475–1495 (2021).
doi: 10.1016/j.annonc.2021.09.019 pubmed: 34678411
Dijkers, E. C. et al. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin. Pharm. Ther. 87, 586–592 (2010).
doi: 10.1038/clpt.2010.12
Bensch, F. et al. (89)Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up. Eur. J. Nucl. Med. Mol. Imaging 45, 2300–2306 (2018).
doi: 10.1007/s00259-018-4099-8 pubmed: 30058029 pmcid: 6208812
Gebhart, G. et al. 18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO. J. Nucl. Med. 54, 1862–1868 (2013).
doi: 10.2967/jnumed.112.119271 pubmed: 24092940
Perez-Garcia, J. M. et al. Chemotherapy de-escalation using an (18)F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial. Lancet Oncol. 22, 858–871 (2021).
doi: 10.1016/S1470-2045(21)00122-4 pubmed: 34019819
Gebhart, G. et al. Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial. Ann. Oncol. 27, 619–624 (2016).
doi: 10.1093/annonc/mdv577 pubmed: 26598545
Mullard, A. Parsing exceptional responders. Nat. Rev. Drug Discov. 20, 8 (2021).
pubmed: 33277625
Perez, E. A. et al. Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine +/- pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer. BMC Cancer 19, 517 (2019).
doi: 10.1186/s12885-019-5687-0 pubmed: 31146717 pmcid: 6543580
Wimana, Z. et al. Mucolytic agents can enhance HER2 receptor accessibility for [(89)Zr]trastuzumab, improving HER2 imaging in a mucin-overexpressing breast cancer xenograft mouse model. Mol. Imaging Biol. 17, 697–703 (2015).
doi: 10.1007/s11307-015-0840-x pubmed: 25761907
Palyi-Krekk, Z. et al. Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer. Eur. J. Cancer 43, 2423–2433 (2007).
doi: 10.1016/j.ejca.2007.08.018 pubmed: 17911008
Modi, S. et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N. Engl. J. Med. 387, 9–20 (2022).
doi: 10.1056/NEJMoa2203690 pubmed: 35665782 pmcid: 10561652
Ogitani, Y., Hagihara, K., Oitate, M., Naito, H. & Agatsuma, T. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 107, 1039–1046 (2016).
doi: 10.1111/cas.12966 pubmed: 27166974 pmcid: 4946713
Imaging patients for cancer drug selection—metastatic breast cancer (IMPACT-MBC). ClinicalTrials.gov identifier: NCT01957332. Updated January 5, 2022. Accessed 27 April 2023 ( https://ClinicalTrials.gov/show/NCT01957332 ).
Hunter, F. W. et al. Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer. Br. J. Cancer 122, 603–612 (2020).
doi: 10.1038/s41416-019-0635-y pubmed: 31839676
De Bleser, E. et al. A trial-based cost-utility analysis of metastasis-directed therapy for oligorecurrent prostate cancer. Cancers 12, 132 (2020).
doi: 10.3390/cancers12010132 pubmed: 31947974 pmcid: 7016808
Sussman, M., Yu, J. C. & Menzin, J. Do research groups align on an intervention’s value? Concordance of cost-effectiveness findings between the institute for clinical and economic review and other health system stakeholders. Appl. Health Econ. Health Policy 18, 477–489 (2020).
doi: 10.1007/s40258-019-00545-9 pubmed: 31919779
Dehdashti, F. et al. Evaluation of [(89)Zr]trastuzumab-PET/CT in differentiating HER2-positive from HER2-negative breast cancer. Breast Cancer Res. Treat. 169, 523–530 (2018).
doi: 10.1007/s10549-018-4696-z pubmed: 29442264 pmcid: 5955803
Boellaard, R. et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur. J. Nucl. Med. Mol. Imaging 42, 328–354 (2015).
doi: 10.1007/s00259-014-2961-x pubmed: 25452219
Makris, N. E. et al. Multicenter harmonization of 89Zr PET/CT performance. J. Nucl. Med. 55, 264–267 (2014).
doi: 10.2967/jnumed.113.130112 pubmed: 24357686
Therasse, P. et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl Cancer Inst. 92, 205–216 (2000).
doi: 10.1093/jnci/92.3.205 pubmed: 10655437
Young, H. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations.Eur. J. Cancer 35, 1773–1782 (1999).
doi: 10.1016/S0959-8049(99)00229-4 pubmed: 10673991
Wahl, R. L., Jacene, H., Kasamon, Y. & Lodge, M. A. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J. Nucl. Med. 50, 122S–150S (2009).
doi: 10.2967/jnumed.108.057307 pubmed: 19403881
Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228–247 (2009).
doi: 10.1016/j.ejca.2008.10.026 pubmed: 19097774

Auteurs

Magdalena Mileva (M)

Department of Nuclear Medicine, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, Belgium.
ORCID: 0000-0002-9929-4576

Elisabeth G E de Vries (EGE)

Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

Thomas Guiot (T)

Department of Medical Physics, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, Belgium.

Zéna Wimana (Z)

Department of Nuclear Medicine, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, Belgium.
Department of Radiopharmacy, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, Belgium.

Anne-Leen Deleu (AL)

Department of Nuclear Medicine, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, Belgium.

Carolien P Schröder (CP)

Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Department of Medical Oncology, Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam, The Netherlands.

Yolene Lefebvre (Y)

Department of Radiology, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, Belgium.

Marianne Paesmans (M)

Data Center, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, Belgium.

Sigrid Stroobants (S)

Department of Nuclear Medicine, Antwerp University Hospital, Edegem, Belgium.

Manon Huizing (M)

Department of Medical Oncology, Antwerp University Hospital, Edegem, Belgium.

Philippe Aftimos (P)

Department of Medical Oncology, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, Belgium.

Jolien Tol (J)

Department of Internal Medicine, Jeroen Bosch Ziekenhuis, Den Bosch, The Netherlands.

Winette T A Van der Graaf (WTA)

Department of Medical Oncology, Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam, The Netherlands.
Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands.

Wim J G Oyen (WJG)

Humanitas Clinical and Research Center, Humanitas University, Milan, Italy.
Department of Radiology and Nuclear Medicine, Rijnstate Hospital, Arnhem, The Netherlands.
Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.

Danielle J Vugts (DJ)

Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit, Cancer Center Amsterdam, Amsterdam, The Netherlands.

C Willemien Menke-van der Houven van Oordt (CW)

Department of Medical Oncology, Amsterdam UMC Location VUMC, Cancer Centre Amsterdam, Amsterdam, The Netherlands.

Adrienne H Brouwers (AH)

Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
ORCID: 0000-0003-2698-1516

Martine Piccart-Gebhart (M)

Department of Medical Oncology, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, Belgium.

Patrick Flamen (P)

Department of Nuclear Medicine, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, Belgium.

Géraldine Gebhart (G)

Department of Nuclear Medicine, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, Belgium. geraldine.gebhart@hubruxelles.be.
ORCID: 0000-0001-8853-0783

Classifications MeSH